<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="11" family="Helvetica-Black,Bold" color="#ffffff"/>
	<fontspec id="font1" size="8" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font2" size="8" family="AkzidenzGroteskBE-Md,Bold" color="#000000"/>
	<fontspec id="font3" size="8" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font4" size="8" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font5" size="2" family="AkzidenzGroteskBE" color="#ffffff"/>
	<fontspec id="font6" size="15" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font7" size="16" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font8" size="16" family="AkzidenzGroteskBE,BoldItalic" color="#000000"/>
	<fontspec id="font9" size="12" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font10" size="12" family="GeorgiaExt" color="#000000"/>
	<fontspec id="font11" size="6" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font12" size="8" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
	<fontspec id="font13" size="11" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font14" size="9" family="AkzidenzGroteskBE-Md,Bold" color="#000000"/>
	<fontspec id="font15" size="9" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font16" size="9" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
	<fontspec id="font17" size="9" family="AkzidenzGroteskBE,Bold" color="#000000"/>
<text top="85" left="477" width="78" height="10" font="font0" id="p1_t1" reading_order_no="2" segment_no="1" tag_type="title"><a href="http://www.biomedcentral.com/info/about/charter/"><b>Open Access</b></a></text>
<text top="42" left="306" width="62" height="7" font="font1" id="p1_t2" reading_order_no="0" segment_no="0" tag_type="text"><b>Available online</b></text>
<text top="42" left="370" width="186" height="7" font="font3" id="p1_t3" reading_order_no="1" segment_no="0" tag_type="text">http://breast-cancer-research.com/content/7/6/R1023</text>
<text top="735" left="569" width="23" height="8" font="font4" id="p1_t4" reading_order_no="119" segment_no="25" tag_type="text">R1023</text>
<text top="85" left="57" width="9" height="2" font="font5" id="p1_t5" reading_order_no="4" segment_no="2" tag_type="title">Vol 7 No 6</text>
<text top="85" left="57" width="103" height="14" font="font6" id="p1_t6" reading_order_no="3" segment_no="2" tag_type="title">Research article</text>
<text top="102" left="57" width="236" height="14" font="font7" id="p1_t7" reading_order_no="5" segment_no="3" tag_type="title"><b>A common missense variant in </b></text>
<text top="102" left="293" width="59" height="14" font="font8" id="p1_t8" reading_order_no="6" segment_no="3" tag_type="title"><i><b>BRCA2 </b></i></text>
<text top="102" left="351" width="204" height="14" font="font7" id="p1_t9" reading_order_no="7" segment_no="3" tag_type="title"><b>predisposes to early onset </b></text>
<text top="120" left="57" width="103" height="14" font="font7" id="p1_t10" reading_order_no="8" segment_no="3" tag_type="title"><b>breast cancer</b></text>
<text top="138" left="57" width="77" height="11" font="font9" id="p1_t11" reading_order_no="9" segment_no="4" tag_type="text">Bohdan Górski</text>
<text top="137" left="134" width="5" height="8" font="font3" id="p1_t12" reading_order_no="10" segment_no="4" tag_type="text">1</text>
<text top="138" left="139" width="87" height="11" font="font9" id="p1_t13" reading_order_no="11" segment_no="4" tag_type="text">, Steven A Narod</text>
<text top="137" left="226" width="5" height="8" font="font3" id="p1_t14" reading_order_no="12" segment_no="4" tag_type="text">2</text>
<text top="138" left="231" width="67" height="11" font="font9" id="p1_t15" reading_order_no="13" segment_no="4" tag_type="text"> and Jan Lubi</text>
<text top="135" left="298" width="7" height="14" font="font10" id="p1_t16" reading_order_no="14" segment_no="4" tag_type="text">ń</text>
<text top="138" left="305" width="14" height="11" font="font9" id="p1_t17" reading_order_no="15" segment_no="4" tag_type="text">ski</text>
<text top="137" left="319" width="5" height="8" font="font3" id="p1_t18" reading_order_no="16" segment_no="4" tag_type="text">1</text>
<text top="171" left="57" width="3" height="5" font="font11" id="p1_t19" reading_order_no="17" segment_no="5" tag_type="text">1</text>
<text top="171" left="60" width="438" height="7" font="font3" id="p1_t20" reading_order_no="18" segment_no="5" tag_type="text">Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland</text>
<text top="180" left="57" width="3" height="5" font="font11" id="p1_t21" reading_order_no="19" segment_no="6" tag_type="text">2</text>
<text top="181" left="60" width="243" height="7" font="font3" id="p1_t22" reading_order_no="20" segment_no="6" tag_type="text">Centre for Research on Women's Health, University of Toronto, Canada</text>
<text top="199" left="57" width="208" height="7" font="font3" id="p1_t23" reading_order_no="21" segment_no="7" tag_type="text">Corresponding author: Steven A Narod, steven.narod@sw.ca</text>
<text top="217" left="57" width="498" height="7" font="font3" id="p1_t24" reading_order_no="22" segment_no="8" tag_type="text">Received: 17 Mar 2005 Revisions requested: 15 Apr 2005 Revisions received: 20 Sep 2005 Accepted: 28 Sep 2005 Published: 24 Oct 2005</text>
<text top="235" left="57" width="85" height="7" font="font12" id="p1_t25" reading_order_no="23" segment_no="9" tag_type="text"><i>Breast Cancer Research</i></text>
<text top="235" left="141" width="25" height="7" font="font3" id="p1_t26" reading_order_no="24" segment_no="9" tag_type="text"> 2005, </text>
<text top="235" left="166" width="4" height="7" font="font2" id="p1_t27" reading_order_no="25" segment_no="9" tag_type="text"><b>7</b></text>
<text top="235" left="171" width="138" height="7" font="font3" id="p1_t28" reading_order_no="26" segment_no="9" tag_type="text">:R1023-R1027 (DOI 10.1186/bcr1338)</text>
<text top="245" left="57" width="265" height="7" font="font3" id="p1_t29" reading_order_no="27" segment_no="10" tag_type="text"><a href="http://breast-cancer-research.com/content/7/6/R1023">This article is online at: http://breast-cancer-research.com/content/7/6/R1023</a></text>
<text top="255" left="57" width="52" height="7" font="font3" id="p1_t30" reading_order_no="28" segment_no="11" tag_type="text">© 2005 Górski</text>
<text top="255" left="109" width="17" height="7" font="font12" id="p1_t31" reading_order_no="29" segment_no="11" tag_type="text"><i> et al</i></text>
<text top="255" left="126" width="107" height="7" font="font3" id="p1_t32" reading_order_no="30" segment_no="11" tag_type="text">.; licensee BioMed Central Ltd. </text>
<text top="265" left="57" width="495" height="7" font="font3" id="p1_t33" reading_order_no="31" segment_no="12" tag_type="text">This is an Open Access article distributed under the terms of the Creative Commons Attribution License<a href="http://creativecommons.org/licenses/by/2.0"> (http://creativecommons.org/licenses/by/</a></text>
<text top="275" left="57" width="426" height="7" font="font3" id="p1_t34" reading_order_no="32" segment_no="12" tag_type="text"><a href="http://creativecommons.org/licenses/by/2.0">2.0),</a> which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</text>
<text top="305" left="57" width="43" height="10" font="font13" id="p1_t35" reading_order_no="33" segment_no="13" tag_type="title"><b>Abstract</b></text>
<text top="325" left="57" width="49" height="8" font="font14" id="p1_t36" reading_order_no="34" segment_no="14" tag_type="text"><b>Introduction</b></text>
<text top="325" left="106" width="66" height="8" font="font15" id="p1_t37" reading_order_no="35" segment_no="14" tag_type="text"> Mutations in the </text>
<text top="325" left="172" width="33" height="8" font="font16" id="p1_t38" reading_order_no="36" segment_no="14" tag_type="text"><i>BRCA2 </i></text>
<text top="325" left="206" width="92" height="8" font="font15" id="p1_t39" reading_order_no="37" segment_no="14" tag_type="text">gene are one of the two</text>
<text top="336" left="57" width="240" height="8" font="font15" id="p1_t40" reading_order_no="38" segment_no="14" tag_type="text">major causes of hereditary breast cancer. Protein-truncating</text>
<text top="346" left="57" width="240" height="8" font="font15" id="p1_t41" reading_order_no="39" segment_no="14" tag_type="text">mutations of BRCA2 are usually deleterious and increase the</text>
<text top="357" left="57" width="240" height="8" font="font15" id="p1_t42" reading_order_no="40" segment_no="14" tag_type="text">risk of breast cancer up to 80% over a lifetime. A few missense</text>
<text top="367" left="57" width="54" height="8" font="font15" id="p1_t43" reading_order_no="41" segment_no="14" tag_type="text">mutations in </text>
<text top="367" left="111" width="33" height="8" font="font16" id="p1_t44" reading_order_no="42" segment_no="14" tag_type="text"><i>BRCA2 </i></text>
<text top="367" left="147" width="151" height="8" font="font15" id="p1_t45" reading_order_no="43" segment_no="14" tag_type="text">are believed to have a similarly high</text>
<text top="378" left="57" width="240" height="8" font="font15" id="p1_t46" reading_order_no="44" segment_no="14" tag_type="text">penetrance, apart from more common neutral polymorphisms. It</text>
<text top="388" left="57" width="240" height="8" font="font15" id="p1_t47" reading_order_no="45" segment_no="14" tag_type="text">is often difficult to classify a particular sequence variant as a</text>
<text top="399" left="57" width="240" height="8" font="font15" id="p1_t48" reading_order_no="46" segment_no="14" tag_type="text">mutation or a polymorphism. For a deleterious variant, one would</text>
<text top="409" left="57" width="240" height="8" font="font15" id="p1_t49" reading_order_no="47" segment_no="14" tag_type="text">expect a greater allele frequency in breast cancer cases than in</text>
<text top="420" left="57" width="240" height="8" font="font15" id="p1_t50" reading_order_no="48" segment_no="14" tag_type="text">ethnic-matched controls. In contrast, neutral polymorphic</text>
<text top="430" left="57" width="204" height="8" font="font15" id="p1_t51" reading_order_no="49" segment_no="14" tag_type="text">variants should be equally frequent in the two groups.</text>
<text top="451" left="57" width="36" height="8" font="font14" id="p1_t52" reading_order_no="50" segment_no="16" tag_type="text"><b>Methods</b></text>
<text top="451" left="92" width="205" height="8" font="font15" id="p1_t53" reading_order_no="51" segment_no="16" tag_type="text"> We genotyped 3,241 cases of breast cancer</text>
<text top="462" left="57" width="240" height="8" font="font15" id="p1_t54" reading_order_no="52" segment_no="16" tag_type="text">diagnosed at under 51 years of age, unselected for family</text>
<text top="472" left="57" width="240" height="8" font="font15" id="p1_t55" reading_order_no="53" segment_no="16" tag_type="text">history, from 18 hospitals throughout Poland and 2,791 ethnic-</text>
<text top="483" left="57" width="113" height="8" font="font15" id="p1_t56" reading_order_no="54" segment_no="16" tag_type="text">matched controls for a single </text>
<text top="483" left="170" width="33" height="8" font="font16" id="p1_t57" reading_order_no="55" segment_no="16" tag_type="text"><i>BRCA2 </i></text>
<text top="483" left="203" width="62" height="8" font="font15" id="p1_t58" reading_order_no="56" segment_no="16" tag_type="text">C5972T variant.</text>
<text top="325" left="315" width="31" height="8" font="font14" id="p1_t59" reading_order_no="57" segment_no="15" tag_type="text"><b>Results</b></text>
<text top="325" left="346" width="210" height="8" font="font15" id="p1_t60" reading_order_no="58" segment_no="15" tag_type="text"> The variant was present in approximately 6% of the</text>
<text top="336" left="315" width="240" height="8" font="font15" id="p1_t61" reading_order_no="59" segment_no="15" tag_type="text">Polish population. In the study, 13 women (11 cases and two</text>
<text top="346" left="315" width="240" height="8" font="font15" id="p1_t62" reading_order_no="60" segment_no="15" tag_type="text">controls (OR = 4.7; p = 0.02)) were homozygous for the variant</text>
<text top="357" left="315" width="240" height="8" font="font15" id="p1_t63" reading_order_no="61" segment_no="15" tag_type="text">allele. The overall odds ratio for breast cancer in women with a</text>
<text top="367" left="315" width="72" height="8" font="font15" id="p1_t64" reading_order_no="62" segment_no="15" tag_type="text">single copy of the </text>
<text top="367" left="387" width="33" height="8" font="font16" id="p1_t65" reading_order_no="63" segment_no="15" tag_type="text"><i>BRCA2 </i></text>
<text top="367" left="421" width="135" height="8" font="font15" id="p1_t66" reading_order_no="64" segment_no="15" tag_type="text">C5972T variant was 1.1 (p = 0.7);</text>
<text top="378" left="315" width="240" height="8" font="font15" id="p1_t67" reading_order_no="65" segment_no="15" tag_type="text">however, the effect was significant for patients diagnosed at or</text>
<text top="388" left="315" width="240" height="8" font="font15" id="p1_t68" reading_order_no="66" segment_no="15" tag_type="text">before age 40 (OR = 1.4; p = 0.04). We reviewed the</text>
<text top="399" left="315" width="98" height="8" font="font15" id="p1_t69" reading_order_no="67" segment_no="15" tag_type="text">association between the </text>
<text top="399" left="413" width="33" height="8" font="font16" id="p1_t70" reading_order_no="68" segment_no="15" tag_type="text"><i>BRCA2 </i></text>
<text top="399" left="447" width="109" height="8" font="font15" id="p1_t71" reading_order_no="69" segment_no="15" tag_type="text">variant in different histologic</text>
<text top="409" left="315" width="241" height="8" font="font15" id="p1_t72" reading_order_no="70" segment_no="15" tag_type="text">subgroups and found the effect most pronounced in women</text>
<text top="420" left="315" width="108" height="8" font="font15" id="p1_t73" reading_order_no="71" segment_no="15" tag_type="text">who had ductal carcinoma </text>
<text top="420" left="423" width="28" height="8" font="font16" id="p1_t74" reading_order_no="72" segment_no="15" tag_type="text"><i>in situ </i></text>
<text top="420" left="452" width="104" height="8" font="font15" id="p1_t75" reading_order_no="73" segment_no="15" tag_type="text">(DCIS) with micro-invasion</text>
<text top="430" left="315" width="93" height="8" font="font15" id="p1_t76" reading_order_no="74" segment_no="15" tag_type="text">(OR = 2.8; p &lt; 0.0001).</text>
<text top="451" left="315" width="46" height="8" font="font14" id="p1_t77" reading_order_no="75" segment_no="17" tag_type="text"><b>Conclusion</b></text>
<text top="451" left="361" width="19" height="8" font="font15" id="p1_t78" reading_order_no="76" segment_no="17" tag_type="text"> The </text>
<text top="451" left="380" width="33" height="8" font="font16" id="p1_t79" reading_order_no="77" segment_no="17" tag_type="text"><i>BRCA2 </i></text>
<text top="451" left="413" width="142" height="8" font="font15" id="p1_t80" reading_order_no="78" segment_no="17" tag_type="text">C5972T allele is a common variant in</text>
<text top="462" left="315" width="240" height="8" font="font15" id="p1_t81" reading_order_no="79" segment_no="17" tag_type="text">Poland that increases the risk of DCIS with micro-invasion. The</text>
<text top="472" left="315" width="241" height="8" font="font15" id="p1_t82" reading_order_no="80" segment_no="17" tag_type="text">homozygous state is rare but increases the risk of breast cancer</text>
<text top="483" left="315" width="32" height="8" font="font15" id="p1_t83" reading_order_no="81" segment_no="17" tag_type="text">five-fold.</text>
<text top="532" left="57" width="64" height="10" font="font13" id="p1_t84" reading_order_no="82" segment_no="18" tag_type="title"><b>Introduction</b></text>
<text top="544" left="57" width="240" height="9" font="font15" id="p1_t85" reading_order_no="83" segment_no="20" tag_type="text">There are several approaches to identifying low-penetrance</text>
<text top="556" left="57" width="240" height="9" font="font15" id="p1_t86" reading_order_no="84" segment_no="20" tag_type="text">candidate genes for breast cancer. In one approach, it is</text>
<text top="567" left="57" width="240" height="9" font="font15" id="p1_t87" reading_order_no="85" segment_no="20" tag_type="text">assumed that missense variants of genes for which truncating</text>
<text top="579" left="57" width="240" height="9" font="font15" id="p1_t88" reading_order_no="86" segment_no="20" tag_type="text">mutations are clearly pathogenic might also be deleterious. If</text>
<text top="591" left="57" width="240" height="9" font="font15" id="p1_t89" reading_order_no="87" segment_no="20" tag_type="text">the missense allele demonstrates high penetrance (i.e. like</text>
<text top="603" left="57" width="240" height="9" font="font15" id="p1_t90" reading_order_no="88" segment_no="20" tag_type="text">truncating mutations), then it will be relatively straightforward</text>
<text top="614" left="57" width="240" height="9" font="font15" id="p1_t91" reading_order_no="89" segment_no="20" tag_type="text">to establish the association when allele frequency is high. If the</text>
<text top="626" left="57" width="240" height="9" font="font15" id="p1_t92" reading_order_no="90" segment_no="20" tag_type="text">penetrance of the missense variant is low, however, then the</text>
<text top="638" left="57" width="240" height="9" font="font15" id="p1_t93" reading_order_no="91" segment_no="20" tag_type="text">association may be missed if only a small number of cancers</text>
<text top="650" left="57" width="240" height="9" font="font15" id="p1_t94" reading_order_no="92" segment_no="20" tag_type="text">is studied and the variant may falsely be classified as a neutral</text>
<text top="661" left="57" width="240" height="9" font="font15" id="p1_t95" reading_order_no="93" segment_no="20" tag_type="text">polymorphism. We are in the process of establishing a large</text>
<text top="673" left="57" width="240" height="9" font="font15" id="p1_t96" reading_order_no="94" segment_no="20" tag_type="text">database of breast cancer cases and ethnic-matched controls</text>
<text top="685" left="57" width="240" height="9" font="font15" id="p1_t97" reading_order_no="95" segment_no="20" tag_type="text">in order to evaluate the pathogenicity of the common founder</text>
<text top="697" left="57" width="240" height="9" font="font15" id="p1_t98" reading_order_no="96" segment_no="20" tag_type="text">alleles of the most important cancer susceptibility genes. Sev-</text>
<text top="532" left="315" width="240" height="9" font="font15" id="p1_t99" reading_order_no="97" segment_no="19" tag_type="text">eral deleterious founder alleles have been identified in</text>
<text top="544" left="315" width="31" height="9" font="font16" id="p1_t100" reading_order_no="98" segment_no="19" tag_type="text"><i>BRCA1</i></text>
<text top="544" left="347" width="140" height="9" font="font15" id="p1_t101" reading_order_no="99" segment_no="19" tag_type="text">, but to date, no founder mutation in </text>
<text top="544" left="486" width="34" height="9" font="font16" id="p1_t102" reading_order_no="100" segment_no="19" tag_type="text"><i>BRCA2 </i></text>
<text top="544" left="520" width="36" height="9" font="font15" id="p1_t103" reading_order_no="101" segment_no="19" tag_type="text">has been</text>
<text top="556" left="315" width="240" height="9" font="font15" id="p1_t104" reading_order_no="102" segment_no="19" tag_type="text">iden<a href="">tified [1-3]. Th</a>ere are a few common variant alleles in</text>
<text top="567" left="315" width="34" height="9" font="font16" id="p1_t105" reading_order_no="103" segment_no="19" tag_type="text"><i>BRCA2 </i></text>
<text top="567" left="349" width="207" height="9" font="font15" id="p1_t106" reading_order_no="104" segment_no="19" tag_type="text">in Poland; one of these (C5972T) changes the amino</text>
<text top="579" left="315" width="240" height="9" font="font15" id="p1_t107" reading_order_no="105" segment_no="19" tag_type="text">acid sequence of BRCA2 from threonine to methionine at</text>
<text top="591" left="315" width="241" height="9" font="font15" id="p1_t108" reading_order_no="106" segment_no="19" tag_type="text">codon 1915. It lies within the range of the BRC encoded by</text>
<text top="603" left="315" width="240" height="9" font="font15" id="p1_t109" reading_order_no="107" segment_no="19" tag_type="text">exon 11 that are thought to be involved in binding to RAD51</text>
<text top="614" left="315" width="240" height="9" font="font15" id="p1_t110" reading_order_no="108" segment_no="19" tag_type="text"><a href="">[4]</a>. We sought to determine whether this common missense</text>
<text top="626" left="315" width="227" height="9" font="font15" id="p1_t111" reading_order_no="109" segment_no="19" tag_type="text">BRCA2 variant plays a role in breast cancer susceptibility.</text>
<text top="650" left="315" width="121" height="10" font="font13" id="p1_t112" reading_order_no="110" segment_no="21" tag_type="title"><b>Materials and methods</b></text>
<text top="662" left="315" width="63" height="8" font="font17" id="p1_t113" reading_order_no="111" segment_no="22" tag_type="title"><b>Study subjects</b></text>
<text top="673" left="315" width="240" height="9" font="font15" id="p1_t114" reading_order_no="112" segment_no="23" tag_type="text">The study population included prospectively ascertained</text>
<text top="685" left="315" width="241" height="9" font="font15" id="p1_t115" reading_order_no="113" segment_no="23" tag_type="text">cases of invasive breast cancer diagnosed at 50 years of age</text>
<text top="697" left="315" width="240" height="9" font="font15" id="p1_t116" reading_order_no="114" segment_no="23" tag_type="text">or less at 18 treatment centers throughout Poland between</text>
<text top="724" left="57" width="87" height="7" font="font3" id="p1_t117" reading_order_no="115" segment_no="24" tag_type="footnote">DCIS = ductal carcinoma </text>
<text top="724" left="144" width="20" height="7" font="font12" id="p1_t118" reading_order_no="116" segment_no="24" tag_type="footnote"><i>in situ</i></text>
<text top="724" left="165" width="391" height="7" font="font3" id="p1_t119" reading_order_no="117" segment_no="24" tag_type="footnote">; LOH = loss of heterozygosity; OR = odds ratio; RFLP-PCR = restriction fragment length polymorphism polymerase </text>
<text top="734" left="57" width="49" height="7" font="font3" id="p1_t120" reading_order_no="118" segment_no="24" tag_type="footnote">chain reaction.</text>
</page>
</pdf2xml>
